Opportunities to set-up API production facilities in LatAm to serve this region
via Business Wire
By 2012, the value of the India’s pharmaceutical market is expected to reach an impressive US$17.8bn mark, an increase from the current figure of US$12.2bn. Clearly, the market allows plenty of commercial opportunities. However, industry consolidation around a handful of large domestic players would squeeze smaller companies. Indeed, industry leaders, including Ranbaxy and Dr Reddy’s Laboratories, have continued to be active in early 2008. The latter launched a non-steroidal anti-inflammatory drug (NSAID) Supanac (diclofenac potassium). Supanac, in-licensed from Swiss Applied Pharma Research (APR), targets the US$688mn NSAID market, with two other leading NSAID brands produced by Dr Reddy’s, namely Nise (nimesulide) and Retoz (etoricoxib). Similarly, the domestic active pharmaceutical ingredient (API) industry is showing signs of expansion. In January 2008, Indian firm Dishman Pharmaceuticals and Chemicals reported its plan to build an API plant in China, in an effort to further penetrate the rapidly expanding contract research and manufacturing services (CRAMS) market. In the same month, Israeli generics giant Teva revealed its intention to strengthen its presence in Asia by specifically choosing India for API production. India, which already has over 200 good manufacturing practice (GMP) facilities, the highest number outside the US, is posing a strong challenge to China as the largest global API supplier.
Popularity: 3% [?]
I met a company Mondo Frizzatta in Rosario, Argenina earlier this week. The founders had earlier started an IT comany, Neoris and sold it to CEMEX. Adolfo, one of the founders, is also an Endeavor entrepreneur.
I was telling them about the craze for Italian food – in young, urban India. Little Italy in Bangalore was always crowded with diners.
Frizzatta has a line of frozen pizzas, calzones and empanadas (Argentine samosa!) – products are sold in supermarkets and movie theaters. (Ready-to-eat in 2 minutes). Very tasty – I sampled their entire product lin.
Frizzatta are interested in tailoring those products for Indian markets. With an Italian name, no need of brand name changes. Interesting proposition for partnerships/JVs with Indian food-service companies.
India eNews – Papa John’s to open 100 pizza outlets in India
‘The Indian market is growing and the number of total pizza outlets in last 8-9 years has grown by 15-20 percent [annually]. I expect it to grow even faster at 25-40 percent this year.’
Popularity: 1% [?]
Possibilities exist for acquiring Argentine pharma companies outright and using that as a base to serve the huge Brazilian market. Where multinationals fear to tread, Indian pharma companies with their cost, scale advantage can do well. Import of finished drugs into Argentina is banned. Active pharma ingredients can be imported.
via Business Wire
Continued infusions of cash by the Brazilian government into public healthcare, and broader positive growth dynamics in Latin America – along with relative weakness in the peso – were the main drivers of exports for Argentine producers. Another reason for looking abroad are the continued persistence of price controls on medicines in Argentina – a major deterrent for multinationals – and more cheeringly, some signs of a harder line being taken by medicines regulator ANMAT.
Back in December, we upgraded the country’s Business Environment Rating (BER) for the Approvals Process subcategory from 4 to 6. Our reappraisal was triggered by the announcement that Argentina will become the first Latin American member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, along with broader improvements seen in enforcing rules on controversial drugs. In January 2008, Brazil’s ANVISA regulator and ANMAT agreed to harmonise their respective pharmacopoeias, or drug classification and listing systems. This too is a positive move, as ANVISA has emerged as one of the most proactive in the Latin American region in improving methodology and enforcement.
Popularity: 1% [?]
Opportunity to work with Argentine provincial governments
via BusinessWire
Dynamotive Energy Systems Corporation (OTCBB: DYMTF), a leader in biomass-to-biofuel technology, and its subsidiary Dynamotive Latinoamericana S.A., are pleased to announce the execution of contracts for the provision of biomass for two of its proposed plants in the Province of Corrientes in Argentina. The Company further disclosed that it has identified, and has been offered, a site for the project within the Municipality of Virasoro. Negotiations in regard to the site are progressing and are expected to be completed in the near term.
The signing of the biomass supply contract follows months of cooperative work with the Town of Virasoro which has been instrumental in attracting Dynamotive to the region. This represents a key step in the progress toward the development of the project announced in May, 2007.
The contract envisages the delivery by the Municipality of Virasoro of 250,000 wet tonnes (approx. 150,000 dry tonnes) of biomass (sawdust and other forestry operations residues) per year for 10 years.
Popularity: 1% [?]
